Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the treatment of malignant glioma
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basileas tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer).
- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basileas tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer).
- Dr. Marc Engelhardt, Chief Medical Officer, commented: The Orphan Drug Designation of lisavanbulin by the U.S. FDA is an important milestone for the development of lisavanbulin.
- Glioblastoma is associated with a poor prognosis and there are only very limited therapeutic options available.
- Lisavanbulin, as a targeted treatment, could be a useful new approach to expand the treatment options for patients with this devastating disease.